|
|
| Line 1: |
Line 1: |
| {{drugbox
| |
| | IUPAC_name = 2-{[2-(4-chlorophenoxy)-2-methylpropanoyl]oxy}ethyl nicotinate
| |
| | image = Etofibrate svg.png
| |
| | CAS_number = 31637-97-5
| |
| | ATC_prefix = C10
| |
| | ATC_suffix = AB09
| |
| | PubChem = 65777
| |
| | DrugBank =
| |
| | C=18|H=18|Cl=1|N=1|O=5
| |
| | molecular_weight = 363.792 g/mol
| |
| | bioavailability =
| |
| | protein_bound =
| |
| | metabolism = [[Hydrolysis|Hydrolyzed]] to clofibric acid and [[niacin]]
| |
| | elimination_half-life =
| |
| | excretion =
| |
| | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| |
| | pregnancy_US = <!-- A / B / C / D / X -->
| |
| | pregnancy_category=
| |
| | legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| |
| | legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
| |
| | legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
| |
| | legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| |
| | legal_status =
| |
| | routes_of_administration =
| |
| }}
| |
| __NOTOC__
| |
| {{SI}}
| |
| {{CMG}}
| |
|
| |
|
| ==Overview==
| |
| '''Etofibrate''' is a [[fibrate]]. It is a combination of [[clofibrate]] and [[niacin]], linked together by an [[ester]] bond. In the body, clofibrate and niacin separate and are released gradually, in a manner similar to [[Sustained release|controlled-release]] formulations.<ref>{{cite journal |author=Sposito AC, Mansur AP, Maranhão RC, Rodrigues-Sobrinho CR, Coelho OR, Ramires JA |title=Etofibrate but not controlled-release niacin decreases LDL cholesterol and lipoprotein (a) in type IIb dyslipidemic subjects |journal=Braz J Med Biol Res |volume=34 |issue=2 |pages=177–82 |year=2001 |pmid=11175492 |doi=}} [http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2001000200004 Free full text]</ref>
| |
|
| |
| ==References==
| |
| {{reflist|2}}
| |
|
| |
| {{Lipid modifying agents}}
| |
|
| |
| [[Category:Drug]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Fibrates]]
| |